Meeting of the Advisory Committee on Heritable Disorders in Newborns and Children, 1105-1106 [2024-00264]

Download as PDF 1105 Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices TOTAL ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Form name Number of responses per respondent Average burden per response (in hours) Total burden hours Direct Financial Support Program ....................................... Infrastructure Program ......................................................... Multipurpose or Hybrid Program .......................................... 619 219 1,044 1 1 1 619 219 1,044 2.7 4.8 3.1 1,671.3 1,051.2 3,236.4 Total .............................................................................. 1,882 ........................ 1,882 ........................ 5,958.9 HRSA specifically requests comments on: (1) the necessity and utility of the proposed information collection for the proper performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Maria G. Button, Director, Executive Secretariat. [FR Doc. 2024–00210 Filed 1–8–24; 8:45 am] BILLING CODE 4165–15–P registration, https://www.hrsa.gov/ advisory-committees/heritabledisorders/, by the deadline of 12 p.m. ET on Friday, January 26, 2024. Instructions on how to access the meeting via webcast will be provided upon registration. If you are a nonUnited States citizen who would like to attend the January meeting in-person, please contact ACHDNC@hrsa.gov by January 11, 2024. Kim Morrison, Maternal and Child Health Bureau, HRSA, 5600 Fishers Lane, Room, Rockville, Maryland 20857; 301– 822–4978; or ACHDNC@hrsa.gov. FOR FURTHER INFORMATION CONTACT: ACHDNC provides advice and recommendations to the Secretary of Health and Human Services (Secretary) on the development of newborn screening activities, technologies, policies, guidelines, and programs for effectively reducing morbidity and mortality in newborns and children having, or at risk for, heritable disorders. ACHDNC reviews and reports regularly on newborn and childhood screening practices, recommends improvements in the national newborn and childhood screening programs, and fulfills requirements stated in the authorizing legislation. In addition, ACHDNC’s recommendations regarding inclusion of additional conditions for screening on the Recommended Uniform Screening Panel (RUSP), following adoption by the Secretary, are evidence-informed preventive health services provided for in the comprehensive guidelines supported by HRSA pursuant to section 2713 of the Public Health Service Act (42 U.S.C. 300gg–13). Under this provision, non-grandfathered group health plans and health insurance issuers offering non-grandfathered group or individual health insurance are required to provide insurance coverage without cost-sharing (a co-payment, coinsurance, or deductible) for preventive services for plan years (i.e., policy years) beginning on or after the date that is one year from the Secretary’s adoption of the condition for screening. SUPPLEMENTARY INFORMATION: DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Meeting of the Advisory Committee on Heritable Disorders in Newborns and Children Health Resources and Services Administration (HRSA), Department of Health and Human Services. ACTION: Notice. AGENCY: In accordance with section 1111(g) of the Public Health Service Act, and the Federal Advisory Committee Act, this notice announces that the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC or Committee) has scheduled a public meeting. Information about the ACHDNC and the agenda for this meeting can be found on the ACHDNC website at https://www.hrsa.gov/ advisory-committees/heritabledisorders/. DATES: Monday, January 29, 2024, from 10 a.m. to 5 p.m. Eastern Time (ET) and Tuesday, January 30, 2024, from 10 a.m. to 3 p.m. ET. ADDRESSES: This meeting will be held in person with webcast options. While this meeting is open to the public, advance registration is required. Please visit the ACHDNC website for information on SUMMARY: khammond on DSKJM1Z7X2PROD with NOTICES Total responses VerDate Sep<11>2014 16:38 Jan 08, 2024 Jkt 262001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 During the January 29–30, 2024, meeting, ACHDNC will hear from experts in the fields of public health, medicine, heritable disorders, rare disorders, and newborn screening. Agenda items include the following topics: (1) A possible presentation on qualitative research that focuses on family perspectives; (2) Updates from Committee ad hoc topic groups. Potential topics include: the nomination process and revisions to the decision matrix; (3) An update on the evidence review of Duchenne muscular dystrophy nomination; and (4) Presentation of the final evidencebased review report on the Krabbe disease condition nomination for possible inclusion on the RUSP. Following this report presentation, the ACHDNC expects to vote on the second meeting day, on January 30, 2024, whether to recommend to the Secretary adding Krabbe disease to the RUSP (with potential implications under section 2713 of the Public Health Service Act, as noted above). The agenda for this meeting includes a potential vote to recommend a nominated condition (Krabbe disease) be added by the Secretary to the RUSP. Agenda items are subject to change as priorities dictate. Information about the ACHDNC, including a roster of members and past meeting summaries, is also available on the ACHDNC website. Members of the public also will have the opportunity to provide comments on any or all of the above agenda items. Public participants may request to provide general oral comments and may submit written statements in advance of the scheduled meeting. Oral comments will be honored in the order they are requested and may be limited as time allows. Subject to change: members of the public registered to submit oral public comments on Krabbe disease are tentatively scheduled to provide their statements on Tuesday, January 30, 2024. Members of the public registered to provide oral public comments on all other newborn screening related topics are tentatively scheduled to provide E:\FR\FM\09JAN1.SGM 09JAN1 1106 Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices their statements on Monday, January 29, 2024. Requests to provide a written statement or make oral comments to ACHDNC must be submitted via the registration website by 12 p.m. ET on Tuesday, January 17, 2024. Written comments will be shared with the Committee prior to the meeting so that they have an opportunity to consider them in advance of the meeting. Individuals who need special assistance or another reasonable accommodation should notify Kim Morrison at the address and phone number listed above at least 10 business days prior to the meeting. Since this meeting occurs in a federal government building, attendees must go through a security check to enter the building. Non-United States Citizen attendees must notify HRSA of their planned attendance at least 15 business days prior to the meeting in order to facilitate their entry into the building. All attendees are required to present government-issued identification prior to entry. Extramural Research, National Eye Institute, National Institutes of Health, 6700 B Rockledge Dr., Rockville, MD 20892, 301– 451–2020, hoshawb@mail.nih.gov. Name of Committee: National Eye Institute Special Emphasis Panel; Clinical Applications. Date: February 27, 2024. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Eye Institute, 6700 Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Ashley Fortress, Ph.D., Designated Federal Official, Division of Extramural Activities, National Eye Institute, National Institutes of Health, 6700 B Rockledge Dr., Bethesda, MD 20817, (301) 451–2020 ashley.fortress@nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.867, Vision Research, National Institutes of Health, HHS) Dated: January 4, 2024. Victoria E. Townsend, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–00212 Filed 1–8–24; 8:45 am] BILLING CODE 4140–01–P Maria G. Button, Director, Executive Secretariat. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2024–00264 Filed 1–8–24; 8:45 am] BILLING CODE 4165–15–P National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Mental Health; Notice of Closed Meetings National Institutes of Health National Eye Institute; Notice of Closed Meetings khammond on DSKJM1Z7X2PROD with NOTICES Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel; Center Core Grant for Vision Research (P30). Date: February 20, 2024. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Eye Institute, 6700B Rockledge Drive, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Brian Hoshaw, Ph.D., Designated Federal Official, Division of VerDate Sep<11>2014 16:38 Jan 08, 2024 Jkt 262001 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Measures to Advance Quality in Mental Health Services. Date: February 6, 2024. Time: 12:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Serena Chu, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 Neuroscience Center, 6001 Executive Blvd. Bethesda, MD 20852, 301–500–5829, serena.chu@nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; NonPharmacological Clinical Trials. Date: February 8, 2024. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Serena Chu, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Bethesda, MD 20852, 301–500–5829, serena.chu@nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01). Date: February 9, 2024. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Rebecca Steiner Garcia, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Bethesda, MD 20892–9608, 301–443–4525, steinerr@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; Early Phase Clinical Trials: Pharma/Device and K Awards. Date: February 22, 2024. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Regina Dolan-Sewell, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Bethesda, MD 20852, (240) 796–6785, regina.dolan-sewell@nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel; BRAIN R01. Date: February 28, 2024. Time: 11:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard Rockville, MD 20852, (Virtual Meeting). Contact Person: EMMA Perez-Costas, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, E:\FR\FM\09JAN1.SGM 09JAN1

Agencies

[Federal Register Volume 89, Number 6 (Tuesday, January 9, 2024)]
[Notices]
[Pages 1105-1106]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00264]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Meeting of the Advisory Committee on Heritable Disorders in 
Newborns and Children

AGENCY: Health Resources and Services Administration (HRSA), Department 
of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with section 1111(g) of the Public Health 
Service Act, and the Federal Advisory Committee Act, this notice 
announces that the Advisory Committee on Heritable Disorders in 
Newborns and Children (ACHDNC or Committee) has scheduled a public 
meeting. Information about the ACHDNC and the agenda for this meeting 
can be found on the ACHDNC website at https://www.hrsa.gov/advisory-committees/heritable-disorders/.

DATES: Monday, January 29, 2024, from 10 a.m. to 5 p.m. Eastern Time 
(ET) and Tuesday, January 30, 2024, from 10 a.m. to 3 p.m. ET.

ADDRESSES: This meeting will be held in person with webcast options. 
While this meeting is open to the public, advance registration is 
required. Please visit the ACHDNC website for information on 
registration, https://www.hrsa.gov/advisory-committees/heritable-disorders/, by the deadline of 12 p.m. ET on Friday, January 
26, 2024. Instructions on how to access the meeting via webcast will be 
provided upon registration. If you are a non-United States citizen who 
would like to attend the January meeting in-person, please contact 
[email protected] by January 11, 2024.

FOR FURTHER INFORMATION CONTACT: Kim Morrison, Maternal and Child 
Health Bureau, HRSA, 5600 Fishers Lane, Room, Rockville, Maryland 
20857; 301-822-4978; or [email protected].

SUPPLEMENTARY INFORMATION: ACHDNC provides advice and recommendations 
to the Secretary of Health and Human Services (Secretary) on the 
development of newborn screening activities, technologies, policies, 
guidelines, and programs for effectively reducing morbidity and 
mortality in newborns and children having, or at risk for, heritable 
disorders. ACHDNC reviews and reports regularly on newborn and 
childhood screening practices, recommends improvements in the national 
newborn and childhood screening programs, and fulfills requirements 
stated in the authorizing legislation. In addition, ACHDNC's 
recommendations regarding inclusion of additional conditions for 
screening on the Recommended Uniform Screening Panel (RUSP), following 
adoption by the Secretary, are evidence-informed preventive health 
services provided for in the comprehensive guidelines supported by HRSA 
pursuant to section 2713 of the Public Health Service Act (42 U.S.C. 
300gg-13). Under this provision, non-grandfathered group health plans 
and health insurance issuers offering non-grandfathered group or 
individual health insurance are required to provide insurance coverage 
without cost-sharing (a co-payment, co-insurance, or deductible) for 
preventive services for plan years (i.e., policy years) beginning on or 
after the date that is one year from the Secretary's adoption of the 
condition for screening.
    During the January 29-30, 2024, meeting, ACHDNC will hear from 
experts in the fields of public health, medicine, heritable disorders, 
rare disorders, and newborn screening. Agenda items include the 
following topics:
    (1) A possible presentation on qualitative research that focuses on 
family perspectives;
    (2) Updates from Committee ad hoc topic groups. Potential topics 
include: the nomination process and revisions to the decision matrix;
    (3) An update on the evidence review of Duchenne muscular dystrophy 
nomination; and
    (4) Presentation of the final evidence-based review report on the 
Krabbe disease condition nomination for possible inclusion on the RUSP. 
Following this report presentation, the ACHDNC expects to vote on the 
second meeting day, on January 30, 2024, whether to recommend to the 
Secretary adding Krabbe disease to the RUSP (with potential 
implications under section 2713 of the Public Health Service Act, as 
noted above).
    The agenda for this meeting includes a potential vote to recommend 
a nominated condition (Krabbe disease) be added by the Secretary to the 
RUSP. Agenda items are subject to change as priorities dictate. 
Information about the ACHDNC, including a roster of members and past 
meeting summaries, is also available on the ACHDNC website.
    Members of the public also will have the opportunity to provide 
comments on any or all of the above agenda items. Public participants 
may request to provide general oral comments and may submit written 
statements in advance of the scheduled meeting. Oral comments will be 
honored in the order they are requested and may be limited as time 
allows. Subject to change: members of the public registered to submit 
oral public comments on Krabbe disease are tentatively scheduled to 
provide their statements on Tuesday, January 30, 2024. Members of the 
public registered to provide oral public comments on all other newborn 
screening related topics are tentatively scheduled to provide

[[Page 1106]]

their statements on Monday, January 29, 2024. Requests to provide a 
written statement or make oral comments to ACHDNC must be submitted via 
the registration website by 12 p.m. ET on Tuesday, January 17, 2024. 
Written comments will be shared with the Committee prior to the meeting 
so that they have an opportunity to consider them in advance of the 
meeting. Individuals who need special assistance or another reasonable 
accommodation should notify Kim Morrison at the address and phone 
number listed above at least 10 business days prior to the meeting.
    Since this meeting occurs in a federal government building, 
attendees must go through a security check to enter the building. Non-
United States Citizen attendees must notify HRSA of their planned 
attendance at least 15 business days prior to the meeting in order to 
facilitate their entry into the building. All attendees are required to 
present government-issued identification prior to entry.

Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024-00264 Filed 1-8-24; 8:45 am]
BILLING CODE 4165-15-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.